Check 35,000+ stocks against 26 valuation models and 37 quality factors

Rapid Dose Therapeutics Corp (RDTCF) fair value: what the stock is really worth

We calculate from audited financials what Rapid Dose Therapeutics Corp is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Aug 21, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · Home Canada · ISIN CA75339A1012

Thin data Aug 21, 2026

Rapid Dose Therapeutics Corp

RDTCF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0203 · Strongly overvalued (−76.1%)

!Quality 34/100

!Mixed Growth (revenue 5y +83.0 %/yr)

!Loss-making · -157.2% net margin (TTM)

!Negative equity (buybacks among others) · negative free cash flow

!Trails peers (2/7)

!Narrow moat 3/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0178 to bull $0.0225 Growth analysisrevenue history, year by year Quality 34/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Rapid Dose Therapeutics Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.

How to read this chart

60‑month range $0.0004 – $1.11 · fair‑value band $0.0178 – $0.0225 · the $0.0850 price screens above the $0.0203 fair value. Dashed = 300-day average. As of Aug 21, 2026.

Follow Rapid Dose Therapeutics in your weekly email

Every Wednesday you see whether Rapid Dose Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release pharmaceuticals, emulsified oils, and over-the-counter medicines into the bloodstream. It also provides over-the-counter products consisting of QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12; and QuickStrip Sleep to deliver melatonin, as well as dental products including Lidocaine QuickStrip, a muco-adhesive oral thin film. It also engages in the research, production, provision, and distribution of technical services for the delivery of oral thin film strips containing active ingredients. In addition, the company is involved in the sale of health and wellness products, such as nutraceuticals; white label manufacturing, including oral thin film strips containing active ingredients under cannabis licensing; and the provision of consulting services for the application of active ingredients with the oral thin film polymer formulation and processes. Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.

Stock analysis

Rapid Dose Therapeutics Corp (RDTCF) currently trades at $0.0850, while our model-based Fair Value estimate is $0.0203, 76.1% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 6 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0178 (bear) to $0.0225 (bull), the price of $0.0850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Rapid Dose Therapeutics Corp reported revenue of C$2.1M in FY2025 versus C$755K in FY2021, a compound +28.9%/yr. Reported net income was −C$5.4M in FY2025.

Key figures

Market cap $11.7M · P/S ratio 0.64 · EPS (TTM) $−0.0100 · Net margin −157% · Return on equity −914% · Return on assets (EBIT) −45.6% · Operating margin −105% · Revenue (TTM) C$2.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 544% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −76%, RDTCF screens richer than that median.

Notify me when RDTCF reaches fair value

Put RDTCF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 34/100

Of which business quality 34 · Market factors (momentum, volatility) 41

Profitability 50

Margins and returns on capital today

Quality Growth 73

Are margins and returns improving?

Cashflow 0

Earnings quality: real cash, not paper profit

Fin. Strength 15

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 44

Price trend over the last 3–12 months (market factor)

52W Momentum 26

Distance to the 52-week high (market factor)

Net Issuance 1

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+104.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+83.0%

Start year 2020 (pandemic)

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−7,501.6% (2020) → −366.6% (2024)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

RDTCF screens overvalued: fair value 76% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Rapid Dose Therapeutics Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks

Beats the industry median on 2/7 measures

Overall it trails its industry peers.

Valuation

Quality Score 34 · Below median

Fair Value upside −76.1% · Bottom 25%

Profitability

Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Return on assets −70.5% · Bottom 25%

Net margin (TTM) −157.2% · Bottom 25%

Operating margin (TTM) −104.8% · Bottom 25%

Growth and dividend

Revenue growth 31.0% · Top 25%

Balance sheet

Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

P/S (TTM) 4.21× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$527.67	$580.44	+10%
Regeneron Pharmaceuticals, Inc REGN	$752.25	$1,275	+69%
argenx SE ARGX	$959.49	$918.60	−4%
CSL Limited CSL	A$176.95	A$194.65	+10%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
BeOne Medicines AG ONC	$360.85	$280.94	−22%
Alnylam Pharmaceuticals, Inc ALNY	$255.96	$217.88	−15%
Royalty Pharma plc RPRX	$58.21	$19.01	−67%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
WuXi Biologics (Cayman) Inc 2269	HK$53.00	HK$58.30	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rapid Dose Therapeutics Corp · Fair Value
$0.0203 −76%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/RDTCF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Rapid Dose Therapeutics Corp · Fair Value</span><br><b style="font-size:20px">$0.0203</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−76%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Rapid Dose Therapeutics Corp Fair Value". https://www.fairvalue-calculator.com/stock/RDTCF

Frequently asked questions

Is Rapid Dose Therapeutics Corp (RDTCF) overvalued or undervalued?

As of Aug 21, 2026, our model estimates a fair value of $0.0203 versus a price of $0.0850, about −76% upside (overvalued).

What is the fair value of RDTCF?

Our model-based fair value for Rapid Dose Therapeutics Corp is $0.0203 (as of Aug 21, 2026), built from audited fundamentals. The current price: $0.0850.

What is the quality score of RDTCF?

Rapid Dose Therapeutics Corp has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Rapid Dose Therapeutics Corp (RDTCF)?

Our model-based price target is the fair value of $0.0203 (as of Aug 21, 2026) from 6 valuation models. Cautious scenario $0.0178, optimistic scenario $0.0225. It is a calculation from audited fundamentals, not an analyst target.

What is the Rapid Dose Therapeutics Corp stock forecast for 2026?

Our models put fair value at $0.0203, about −76% upside versus a price of $0.0850 (overvalued). Cautious scenario $0.0178, optimistic scenario $0.0225. The calculation is refreshed regularly with new filings.

What is the revenue of Rapid Dose Therapeutics Corp (RDTCF)?

Rapid Dose Therapeutics Corp reported trailing-twelve-month revenue of about C$2.8M (latest available figure, as of Aug 21, 2026).

What is the intrinsic value of Rapid Dose Therapeutics Corp (RDTCF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rapid Dose Therapeutics Corp it is $0.0203 per share (as of Aug 21, 2026), against a price of $0.0850. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).

Is Rapid Dose Therapeutics Corp stock overvalued or undervalued in 2026?

As of Aug 21, 2026, RDTCF trades above its calculated fair value: price $0.0850, fair value $0.0203, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of RDTCF?

No. The price is what the market pays today ($0.0850); the fair value is what the company's own numbers justify ($0.0203). For Rapid Dose Therapeutics Corp the two are $0.0647 per share apart. That gap is exactly why we show both numbers side by side.

How much is Rapid Dose Therapeutics Corp worth?

The market values Rapid Dose Therapeutics Corp at about $11.7M (market capitalisation, as of Aug 21, 2026). Per share that is $0.0850; our models calculate a fair value of $0.0203 per share.

What do the bullish and bearish scenarios say about RDTCF?

Our models span a range for Rapid Dose Therapeutics Corp: cautious scenario $0.0178, base $0.0203, optimistic $0.0225 per share (as of Aug 21, 2026, price $0.0850). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Rapid Dose Therapeutics Corp (RDTCF)?

Balance-sheet figures for Rapid Dose Therapeutics Corp (as of Aug 21, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.

How far is RDTCF from its 52-week high?

Rapid Dose Therapeutics Corp trades at $0.0850, about 43% below its 52-week high of $0.1500 and 544% above the low of $0.0132 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0203 is for.

Which stocks are comparable to Rapid Dose Therapeutics Corp?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Rapid Dose Therapeutics Corp stock attractive at the current price?

The data as of Aug 21, 2026: price $0.0850, calculated fair value $0.0203 (−76%), Quality Score 34/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of RDTCF calculated?

We run Rapid Dose Therapeutics Corp through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0203, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.9 % above its aggregate fair value. Rapid Dose Therapeutics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Rapid Dose Therapeutics Corp (RDTCF)?

The closing price on Sep 25, 2026 was $0.0850. Our model-based fair value is $0.0203, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Rapid Dose Therapeutics Corp right now?

The price sits above even our optimistic bull case ($0.0225). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Rapid Dose Therapeutics Corp

How large is the market capitalisation of Rapid Dose Therapeutics Corp (RDTCF)?

The market capitalisation of Rapid Dose Therapeutics Corp is $11.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Rapid Dose Therapeutics Corp (RDTCF)?

The price-to-sales ratio of Rapid Dose Therapeutics Corp is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Rapid Dose Therapeutics Corp (RDTCF)?

Earnings per share at Rapid Dose Therapeutics Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Rapid Dose Therapeutics Corp (RDTCF)?

The net margin of Rapid Dose Therapeutics Corp is −157% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Rapid Dose Therapeutics Corp (RDTCF)?

The return on equity (ROE) of Rapid Dose Therapeutics Corp is −914% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Rapid Dose Therapeutics Corp (RDTCF)?

On an EBIT basis the return on assets of Rapid Dose Therapeutics Corp is −45.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Rapid Dose Therapeutics Corp (RDTCF)?

The operating margin of Rapid Dose Therapeutics Corp is −105% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Rapid Dose Therapeutics Corp (RDTCF)?

Revenue at Rapid Dose Therapeutics Corp is growing +31.0% versus a year earlier (3y avg +6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Rapid Dose Therapeutics Corp (RDTCF) generate?

The free cash flow of Rapid Dose Therapeutics Corp is −C$1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Rapid Dose Therapeutics Corp (RDTCF) carry?

The net debt of Rapid Dose Therapeutics Corp is C$2.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Rapid Dose Therapeutics Corp in the live analysis

One click puts Rapid Dose Therapeutics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.